ANZUP at ASCO 2025 – EVOLUTION

177 Lu-PSMA-617 with ipilimumab and nivolumab in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial

Prof Shahneen Sandhu reported the overall survival results of the EVOLUTION trial that showed the benefits of combining the radioligand therapy ¹⁷⁷Lu-PSMA-617 (LuPSMA) and immunotherapy (nivolumab and ipilimumab) in hard-to-treat and metastatic castrate resistant prostate cancer. LuPSMA is now a standard of care for people affected by this disease, but all will eventually progress on treatment. The promising results showed that by 12 months, 33% of participants who received the combination were free of progressive disease compared to 17% if they received LuPSMA alone. Now, translational work is ongoing to understand the biology of response and to improve patient selection for this combination treatment.